title: The interleukin-6 (IL6)-174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6.
abstract: Septic shock is associated with a high mortality and an excessive activation of immune cascades. Interleukin (IL)-6 has been found to be a key cytokine in the pathogenesis of severe sepsis, but the importance of a regulatory polymorphism within the IL6 promoter has been controversial in these patients. The aim of the study was therefore to systematically investigate the IL6-174 G/C promoter genotype with regard to the presence of shock in patients with sepsis, the IL6 serum levels, and the ex vivo secretion of IL6, respectively. Overall, 112 consecutive subjects with severe sepsis and septic shock according to consensus criteria were enrolled. The ex vivo secretion of IL6 after stimulation with lipopolysaccharide (LPS) in a whole blood assay and the IL6 serum concentrations were determined after admission of the patients. Among the 112 subjects with severe sepsis, 85 patients fulfilled the criteria of septic shock. In these patients, the frequency of the mutated C-allele of the IL6 promoter polymorphism was significantly (P = 0.04) higher compared to that in individuals without shock. IL6 serum concentrations were highest in patients with the GG genotype (mean 2209 pg mL(-1)), followed by CG genotype (mean 1113 pg mL(-1)), and lowest in individuals with the CC genotype (mean 256 pg mL(-1)). Interestingly, a significantly (P = 0.005) higher ex vivo secretion of IL6 is detected in heterozygote individuals (535 pg mL(-1)) and patients with the IL6 CC genotype (555 pg mL(-1)) compared to patients with the -174 GG genotype (276 pg mL(-1)). In conclusion, the IL6-174 G/C promoter genotype is associated with shock in patients with sepsis. Functionally, the mutated C-allele is correlated with low IL6 serum concentrations, but a high ex vivo secretion after LPS stimulation. These results further indicate a complex regulation of the expression of IL6 during infection and have implications for the design of immune intervention trials.
authors.affiliation: Department of Medicine III, University Hospital Aachen, Aachen University (RWTH), Aachen, Germany.
authors.forename: J J W
authors.initials: JJ
authors.lastname: Tischendorf
authors.forename: E
authors.initials: E
authors.lastname: Yagmur
authors.forename: D
authors.initials: D
authors.lastname: Scholten
authors.forename: D
authors.initials: D
authors.lastname: Vidacek
authors.forename: A
authors.initials: A
authors.lastname: Koch
authors.forename: R
authors.initials: R
authors.lastname: Winograd
authors.forename: A M
authors.initials: AM
authors.lastname: Gressner
authors.forename: C
authors.initials: C
authors.lastname: Trautwein
authors.forename: H E
authors.initials: HE
authors.lastname: Wasmuth
authors.forename: F
authors.initials: F
authors.lastname: Lammert
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005786:Gene Expression Regulation; D005838:Genotype; D006801:Humans; D015850:Interleukin-6 / Q000097:blood* / Q000235:genetics*; D008070:Lipopolysaccharides / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D012772:Shock, Septic / Q000235:genetics* / Q000276:immunology* / Q000378:metabolism
chemical_list: D015850:Interleukin-6; D008070:Lipopolysaccharides